Ines Schroeder1, Karl Dichtl2, Uwe Liebchen3, Johannes Wagener4,5, Michael Irlbeck3, Michael Zoller3, Christina Scharf3. 1. Department of Anesthesiology, University Hospital, LMU München, Marchioninistrasse 15, 81377, Munich, Germany. Ines.Schroeder@med.uni-muenchen.de. 2. Max Von Pettenkofer-Institut für Hygiene Und Medizinische Mikrobiologie, LMU München, Medizinische Fakultät, Munich, Germany. 3. Department of Anesthesiology, University Hospital, LMU München, Marchioninistrasse 15, 81377, Munich, Germany. 4. Institut für Hygiene Und Mikrobiologie, Julius-Maximilians-Universität Würzburg, Würzburg, Germany. 5. National Reference Center for Invasive Fungal Infections (NRZMyk), Jena, Germany.
Abstract
BACKGROUND: Galactomannan antigen (GM) testing is widely used in the diagnosis of invasive aspergillosis (IA). Digestive enzymes play an important role in enzyme substitution therapy in exocrine pancreatic insufficiency. As digestive enzymes of fungal origin like Nortase contain enzymes from Aspergillus, a false-positive result of the test might be possible because of cross-reacting antigens of the cell wall of the producing fungi. We, therefore, asked whether the administration of fungal enzymes is a relevant cause of false-positive GM antigen test results. METHODS: Patients with a positive GM antigen test between January 2016 and April 2020 were included in the evaluation and divided into two groups: group 1-Nortase-therapy, group 2-no Nortase-therapy. In addition, dissolved Nortase samples were analyzed in vitro for GM and β-1,3-D-glucan. For statistical analysis, the chi-squared and Mann‒Whitney U tests were used. RESULTS: Sixty-five patients were included in this evaluation (30 patients receiving Nortase and 35 patients not receiving Nortase). The overall false positivity rate of GM testing was 43.1%. Notably, false-positive results were detected significantly more often in the Nortase group (73.3%) than in the control group (17.1%, p < 0.001). While the positive predictive value of GM testing was 0.83 in the control group, there was a dramatic decline to 0.27 in the Nortase group. In vitro analysis proved that the Nortase enzyme preparation was highly positive for the fungal antigens GM and β-1,3-D-glucan. CONCLUSIONS: Our data demonstrate that the administration of digestive enzymes of fungal origin like Nortase leads to a significantly higher rate of false-positive GM test results compared to that in patients without digestive enzyme treatment.
BACKGROUND:Galactomannan antigen (GM) testing is widely used in the diagnosis of invasive aspergillosis (IA). Digestive enzymes play an important role in enzyme substitution therapy in exocrine pancreatic insufficiency. As digestive enzymes of fungal origin like Nortase contain enzymes from Aspergillus, a false-positive result of the test might be possible because of cross-reacting antigens of the cell wall of the producing fungi. We, therefore, asked whether the administration of fungal enzymes is a relevant cause of false-positive GM antigen test results. METHODS:Patients with a positive GM antigen test between January 2016 and April 2020 were included in the evaluation and divided into two groups: group 1-Nortase-therapy, group 2-no Nortase-therapy. In addition, dissolved Nortase samples were analyzed in vitro for GM and β-1,3-D-glucan. For statistical analysis, the chi-squared and Mann‒Whitney U tests were used. RESULTS: Sixty-five patients were included in this evaluation (30 patients receiving Nortase and 35 patients not receiving Nortase). The overall false positivity rate of GM testing was 43.1%. Notably, false-positive results were detected significantly more often in the Nortase group (73.3%) than in the control group (17.1%, p < 0.001). While the positive predictive value of GM testing was 0.83 in the control group, there was a dramatic decline to 0.27 in the Nortase group. In vitro analysis proved that the Nortase enzyme preparation was highly positive for the fungal antigens GM and β-1,3-D-glucan. CONCLUSIONS: Our data demonstrate that the administration of digestive enzymes of fungal origin like Nortase leads to a significantly higher rate of false-positive GM test results compared to that in patients without digestive enzyme treatment.
Authors: A Vena; E Bouza; A Álvarez-Uría; J Gayoso; P Martín-Rabadán; F Cajuste; J Guinea; J Gómez Castellá; R Alonso; P Munoz Journal: Clin Microbiol Infect Date: 2017-05-12 Impact factor: 8.067
Authors: Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett Journal: Clin Infect Dis Date: 2016-08-15 Impact factor: 9.079
Authors: S Y Park; S-H Kim; S-H Choi; H Sung; M-N Kim; J H Woo; Y S Kim; S-K Park; J-H Lee; K-H Lee; S-G Lee; D J Han; S-O Lee Journal: Transpl Infect Dis Date: 2010-02-25 Impact factor: 2.228
Authors: Stijn I Blot; Fabio Silvio Taccone; Anne-Marie Van den Abeele; Pierre Bulpa; Wouter Meersseman; Nele Brusselaers; George Dimopoulos; José A Paiva; Benoit Misset; Jordi Rello; Koenraad Vandewoude; Dirk Vogelaers Journal: Am J Respir Crit Care Med Date: 2012-04-19 Impact factor: 21.405
Authors: Mariska M G Leeflang; Yvette J Debets-Ossenkopp; Junfeng Wang; Caroline E Visser; Rob J P M Scholten; Lotty Hooft; Henk A Bijlmer; Johannes B Reitsma; Mingming Zhang; Patrick M M Bossuyt; Christina M Vandenbroucke-Grauls Journal: Cochrane Database Syst Rev Date: 2015-12-30
Authors: Karl Dichtl; Özlem Koc; Johannes Forster; Christina Scharf; Sebastian Suerbaum; Joachim Andrassy; Johannes Wagener; Ines Schroeder Journal: Infection Date: 2021-06-30 Impact factor: 3.553